✦ LIBER ✦

Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease

✍ Scribed by Paul Rutgeerts; Geert D'Haens; Stephan Targan; Eric Vasiliauskas; Stephen B. Hanauer; Daniel H. Present; Lloyd Mayer; Ruud A. Van Hogezand; Tanja Braakman; Kimberly L. DeWoody; Thomas F. Schaible; Sander J.H. Van Deventer

Book ID: 118521928
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 155 KB
Volume: 117
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(99)70332-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of fistulas in Crohn's disease

Treatment of fistulas in Crohn's disease with infliximab anti-tumor necrosis factor antibodies

✍ A. Kohn; R. Cosintino; M.L. Scribano; A. Andreoli; P. Cerro; C. Prantera 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 164 KB

Endoscopic and histological healing with

Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

✍ Geert D'Haens*; Sander Van Deventer‡; Ruud Van Hogezand §; Douglas Chalmers∥; Ch 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 274 KB

Tumor Necrosis Factor-Alpha Binding Capa

Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease

✍ Ainsworth, Mark A.; Bendtzen, Klaus; Brynskov, Jørn 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 199 KB

MAINTENANCE OF REMISSION WITH INFLIXIMAB

MAINTENANCE OF REMISSION WITH INFLIXIMAB IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS: EFFICACY AND SAFETY LONG-TERM TREATMENT

✍ S. Nasoni; A. Petrolati; N. Altavilla; Z. Rossi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Efficacy and Safety of Tumor Necrosis Fa

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials

✍ Peyrin–Biroulet, Laurent; Deltenre, Pierre; de Suray, Nicolas; Branche, Julien; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 750 KB

Demographic and clinical parameters infl

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn’s disease

✍ Severine Vermeire; Edouard Louis; An Carbonez; Gert Van Assche; Maja Noman; Jacq 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 71 KB